Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing

Journal of Clinical Oncology

Volumn 34, Issue 34, 2016, Pages 4071-4078

  Balmaña, Judith ^a   Digiovanni, Laura ^b   Gaddam, Pragna ^c   Walsh, Michael F ^c   Joseph, Vijai ^c   Stadler, Zsofia K ^c   Nathanson, Katherine L ^b   Garber, Judy E ^d   Couch, Fergus J ^e   Offit, Kenneth ^c   Robson, Mark E ^c   Domchek, Susan M ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CHECKPOINT KINASE 2;

ADULT; ARTICLE; BRIP1 GENE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL LABORATORY; FEMALE; GENE; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; LAW; MAJOR CLINICAL STUDY; MALE; NBN GENE; PALB2 GENE; PATHOGENICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAD51C GENE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; LABORATORY; MEDICAL GENETICS; NEOPLASM; PROSPECTIVE STUDY; REGISTER; STANDARDS;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENETICS, MEDICAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LABORATORIES; MALE; NEOPLASMS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84992447372     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.4316     Document Type: Article

References (24)

1. Easton DF, Pharoah PD, Antoniou AC, et al: Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:2243-2257, 2015
2. Rehm HL, Berg JS, Brooks LD, et al: ClinGen: the Clinical Genome Resource. N Engl J Med 372:2235-2242, 2015
3. Pepin MG, Murray ML, Bailey S, et al: The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories. Genet Med 18:20-24, 2016
4. Jurgens J, Ling H, Hetrick K, et al: Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics. Genet Med 17:782-788, 2015
5. Plon SE, Eccles DM, Easton D, et al: Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282-1291, 2008
6. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424, 2015
7. Landrum MJ, Lee JM, Riley GR, et al: ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42:D980-D985, 2014
8. Landrum MJ, Lee JM, Benson M, et al: ClinVar: Public archive of interpretations of clinically relevant variants. Nucleic Acids Res, 44:D862-D868, 2016
9. Desrichard A, Bidet Y, Uhrhammer N, et al: CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res 13:R119, 2011
10. Liu C, Wang Y, Wang QS, et al: The CHEK2 I157T variant and breast cancer susceptibility: A systematic review and meta-analysis. Asian Pac J Cancer Prev 13:1355-1360, 2012
11. Han FF, Guo CL, Liu LH: The effect of CHEK2 variant I157T on cancer susceptibility: Evidence from a meta-analysis. DNA Cell Biol 32:329-335, 2013
12. Seppälä EH, Ikonen T, Mononen N, et al: CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89:1966-1970, 2003
13. Cybulski C, Górski B, Huzarski T, et al: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135, 2004
14. Falck J, Mailand N, Syljuåsen RG, et al: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842-847, 2001
15. Schwarz JK, Lovly CM, Piwnica-Worms H: Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res 1:598-609, 2003
16. Roeb W, Higgins J, King MC: Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet 21:2738-2744, 2012
17. Stoffel EM, Fearon ER: Germline sequence variants and ovarian cancer: Known-knowns and known-unknowns. JAMA Oncol 2:491-492, 2016
18. Cantor SB, Bell DW, Ganesan S, et al: BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105:149-160, 2001
19. Seal S, Thompson D, Renwick A, et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239-1241, 2006
20. Ramus SJ, Song H, Dicks E, et al: Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 107:djv214, 2015
21. Harrison S, Dolinsky J, Vincent L, et al. Clinical laboratories collaborate to resolve variant interpretation differences in ClinVar. [abstract 2093T]. Baltimore, MD, American Society of Human Genetics American Society of Human Genetics, 2015.
22. Thompson BA, Spurdle AB, Plazzer JP, et al: Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 46:107-115, 2014
23. Eccles DM, Mitchell G, Monteiro AN, et al: BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 26:2057-2065, 2015
24. Fokkema IF, Taschner PE, Schaafsma GC, et al: LOVD v.2.0: The next generation in gene variant databases. Hum Mutat 32:557-563, 2011